Garcia-Tsao G
Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.
Gastroenterologist. 1995 Mar;3(1):41-54.
The pathogenesis of ascites can be divided into (1) factors that favor efflux of fluid from the vascular into the peritoneal space (sinusoidal hypertension, hypoalbuminemia), (2) factors that favor accumulation of fluid in the peritoneal cavity (thoracic duct insufficiency), and (3) factors responsible for repletion of the intravascular volume, and thereby continuous formation of ascites (sodium and water retention). Ascites is perhaps the one complication of cirrhosis with the lowest therapeutic priority. Current therapy of ascites is mainly directed at attaining a negative sodium balance (sodium restriction, diuretics) or at removing intraperitoneal fluid and returning it or its components back to the systemic circulation (large volume paracentesis accompanied by plasma volume expanders, peritoneovenous shunt, ascites "recycling" procedures). Future studies of ascites should investigate the usefulness of peripheral vasoconstrictors and nonsurgical side-to-side portosystemic shunting to relieve sinusoidal hypertension (transjugular intrahepatic portosystemic shunt). More than 90% of patients respond to diuretics and salt restriction. Other therapeutic measures should be directed at the 10% of patients with ascites refractory to diuretics. Prognosis in these patients is poor, and liver transplantation should be contemplated.
(1)促使液体从血管内流入腹腔的因素(肝窦高压、低白蛋白血症);(2)促使液体在腹腔内积聚的因素(胸导管功能不全);(3)负责补充血管内容量并由此持续形成腹水的因素(钠和水潴留)。腹水可能是肝硬化并发症中治疗优先级最低的一种。目前腹水的治疗主要旨在实现负钠平衡(限制钠摄入、使用利尿剂),或去除腹腔内液体并使其或其成分回到体循环(大量腹腔穿刺放液并辅以血浆扩容剂、腹腔静脉分流术、腹水“再循环”程序)。未来对腹水的研究应探讨外周血管收缩剂和非手术性侧侧门体分流术缓解肝窦高压(经颈静脉肝内门体分流术)的有效性。超过90%的患者对利尿剂和限盐治疗有反应。其他治疗措施应针对10%对利尿剂难治的腹水患者。这些患者的预后较差,应考虑肝移植。